The optimal chemoradiation regimen for @entity5 ( @entity1149 ) has not been determined. In this phase I/II study, the use of twice-weekly @entity1311 concomitant with weekly @entity900 and thoracic radiotherapy (RT) was evaluated. @entity1 with @entity5 (without @entity1143 or @entity3799 ) were treated with @entity1514 (60 Gy in 30 fractions over 6 weeks) with concurrent weekly @entity900 20 mg/m(2) and escalating doses of twice-weekly @entity1311 (starting dose of @entity1311 of 20 mg/m(2) increased in increments of 5 mg/m(2)) in successive cohorts of three to six @entity1 until two or more @entity1 experienced dose limiting @entity137 (DLTs) at a particular dose level. All @entity1 were planned to be given a further two cycles of consolidation chemotherapy consisting of @entity1311 175 mg/m(2) and @entity3003 AUC 5 after completion of RT. Twenty-five @entity1 were enrolled in this study from two institutions. At a dose of @entity1311 35 mg/m(2), two of four treated @entity1 had DLTs (1 grade 3 @entity354 and @entity358 ; 1 grade 3 @entity354 and @entity281 ). The recommended dose was therefore determined to be 30 mg/m(2) and a total of 15 @entity1 were enrolled in an expanded cohort at this level. The overall response rate for all @entity1 was 64% (95% CI: 43-82%). The estimated median survival was 23.6 months with an estimated 1-year and 2-year survival of 72 and 49%, respectively. @entity1311 can be safely given twice-weekly at a dose of 30 mg/m(2) in combination with weekly @entity900 (20 mg/m(2)) and @entity1514 (60 Gy), and this regimen has significant activity in @entity5 .

Phase I/II study of concurrent twice-weekly @entity1311 and weekly XXXX with radiation therapy for @entity5 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusion'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage III non-small cell lung cancer', 'stage III NSCLC'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel', 'Paclitaxel'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1514 :: ('MESH:D013896', 'Disease') :: ['thoracic RT'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity3799 :: ('MESH:D002575', 'Disease') :: ['cervical lymphadenopathy'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary toxicity'] @entity354 :: ('MESH:D005764', 'Disease') :: ['oesophagitis']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
